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Résumé 
La scoliose idiopathique de l’adolescent (SIA) est définie comme une courbure de la 
colonne vertébrale supérieure à 10 degrés, qui est de cause inconnue et qui affecte de façon 
prépondérante les adolescents. Des études précédentes sur des modèles murins ont démontré 
une inactivation partielle du gène Pitx1. Cette inactivation partielle provoque une déformation 
spinale sévère lors du développement des souris Pitx1+/-, ce qui est grandement similaire au 
phénotype de la SIA. En se basant sur ces observations, nous postulons que la perte de 
fonction de Pitx1 pourrait avoir un rôle dans la SIA et pourrait être régulée par des 
mécanismes moléculaires spécifiques. En effet, des études faites sur l’expression de Pitx1 
révèlent une perte de son expression dans les ostéoblastes dérivés de patients SIA  au niveau 
de l’ARNm. Nous émettons l’hypothèse que la perte de Pitx1 dans la SIA pourrait être 
déclenchée par des facteurs hypoxiques puisqu’il est connu que Pitx1 est réprimé par 
l’hypoxie et que HIF-2 alpha est surexprimés dans les ostéoblastes des patients SIA même 
dans des conditions normoxiques. De plus, nous avons découvert une mutation dans le 
domaine ODD des HIF-1 alpha chez certains patients SIA (3,1%). Une fonction connue de ce 
domaine est de stabiliser et d’augmenter l’activité transcriptionnelle de HIF-1 alpha dans des 
conditions normoxiques. Nous avons confirmé, par la technique EMSA, l’existence d’un 
élément de réponse fonctionnel à l’hypoxie au niveau du promoteur de Pitx1. Cependant, des 
co-transfections avec des vecteurs d’expression pour HIF-1 alpha et HIF-2 alpha, en présence 
de leur sous-unité beta ARNT, ont conduit à une activation du promoteur de Pitx1 dans la 
lignée cellulaire MG-63 ainsi que dans les ostéoblastes des sujets contrôles. Il est intéressant 
de constater qu’aucune activité du promoteur de Pitx1 dans les ostéoblastes SIA n’a été 
observée, même après la co-expression de HIF-2 alpha et ARNT, confirmant le fait que 
l’expression de Pitx1 est abrogée dans la SIA. Dans l’ensemble, nos résultats démontrent un 
rôle important de Pitx1 dans la SIA et une possible régulation par des facteurs hypoxiques. 
 v
Mots clés: SIA, Pitx1, hypoxie, HIF-1, HIF-2, ARNT, ODDD, osteoblastes, elément de 
réponse à l’hypoxie. 
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Abstract 
 
Adolescent Idiopathic Scoliosis is a lateral curvature of the spine greater than 10 
degrees, with an unknown cause, affecting primarily adolescents. Previous mouse model 
studies showed that partial inactivation of Pitx1 gene resulted in the development of severe 
spinal deformities in Pitx1 +/- mice, which is strikingly similar to the AIS phenotype. Based 
on this observation, we postulated that loss of Pitx1 function might have a role in AIS and 
could be regulated through specific molecular mechanisms. Indeed, expression studies 
revealed a loss of Pitx1 expression in osteoblasts derived from AIS patients, at the mRNA 
level. We hypothesized that the loss of Pitx1 in AIS could be triggered by hypoxic factors, 
since Pitx1 is known to be repressed by hypoxia and that HIF-2 alpha was up regulated in 
AIS osteoblasts even under normoxic conditions. Also, we found a mutation in the ODD 
domain of HIF-1 alpha in some AIS patients (3.1%), which is known to stabilize and 
enhance HIF-1 alpha transcriptional activity in normoxic conditions. We confirmed through 
EMSA the existence of a functional hypoxia response element on Pitx1 promoter. However, 
co-transfection assays with HIF-1 alpha and HIF-2 alpha expression vectors in the presence 
of their beta subunit ARNT led to the activation of Pitx1 promoter in human osteoblast cell 
line MG-63 cells and osteoblasts from control subjects. Interestingly, no Pitx1 promoter 
activity was observed in AIS osteoblasts, even after the co expression of HIF2 alpha and 
ARNT, consolidating the fact that Pitx1 expression is abrogated in AIS. Taken together, our 
findings show an important role for Pitx1 in AIS and hypoxic factors could be one of its 
regulators. 
Keywords: AIS, Pitx1, hypoxia, HIF-1, HIF-2, ARNT, ODDD, Osteoblasts, hypoxia 
response element. 
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Chapter 1. Review of Literature 
 
1.1.1 Scoliosis: Definition  
 
According to the Scoliosis Research Society, the disease Scoliosis is defined as a 
lateral curvature of the spine greater than 10 degrees when measured on a standing 
radiograph. The term Scoliosis originated from its Greek meaning “crookedness”. It is 
characterized by a three dimensional deformity of the spine accompanied by vertebral rotation. 
A few centuries ago, doctors believed that scoliosis was caused by poor posture, nutritional 
deficiency of vitamin D, and five decades back, as a consequence of rickets [1]. 
 
1.1.2 Prevalence: 
 
Scoliosis greater than 10º affects 3-4% of population in North America [2]. Curves 
greater than 30º is found in 0.2% in the population, while the percentage of curves greater than 
45º affects 0.1% [3]. For minor scoliotic curves of 10º, the girls to boys ratio is 4:1. But for 
curves greater than 30º, the girls to boys ratio increases to 10:1. These data suggests that 
scoliotic curves in girls have a greater tendency to progress than in boys [2].  
 
1.1.3 Screening for Scoliosis 
 
Scoliosis screening is done in majority of the schools in North America due to its 
significant percentage of prevalence. Boys and girls aged 13-14 years and 10-12 years 
respectively are screened using Adam’s Forward Bending Test (FBT) in which the child is 
made to bend forward with hands pointing to the toes. Any asymmetry in the contour of the 
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back (rib-humps) can be observed in this position [2]. Once this is detected, a radiograph is 
taken in order to evaluate the child’s condition and determine the severity of the curve. The 
degree of the curve is measured using the Cobb’s angle method, where the most tilted 
vertebrae above and below the apex of the curve is taken into account and the angle between 
the intersecting lines drawn perpendicular to these vertebrae gives the Cobb angle. Once the 
presence of scoliosis is confirmed, the next step is to pinpoint the underlying cause for it, and 
to determine accurately if there is a chance of progression of the curve. Curve progression is 
usually dependent on the gender, skeletal maturity, age at onset, and severity of the curve. 
Girls are ten times more at risk than boys of curve progression, and the risk increases if the 
patient has larger Cobb angle and greater growth potential at the time of detection [3].  
 
1.1.4 Classification of Scoliosis: 
 
Scoliosis is divided into two classes, structural and non structural scoliosis. Non 
structural scoliosis is divided into postural and compensatory scoliosis. Postural scoliosis is 
natural and has a low degree of curvature, while compensatory scoliosis can develop due to 
leg-length inequality. This is compensated by the pelvis leaning towards the shorter limb. 
Structural scoliosis is subdivided into congential scoliosis, secondary scoliosis: curves that are 
secondary to other diseases like syringomyelia, Marfan’s syndrome, or trauma. Idiopathic 
scoliosis; curves without an underlying cause, and is further subdivided based on the age of 
onset of the disease. It is called infantile scoliosis when it occurs in infants up to the age of 
three, juvenile scoliosis between age of three and ten (puberty), and adolescent scoliosis when 
it occurs between puberty and maturity [4]. 
 3
 
1.1.5 Cause: 
 
Scoliosis can result from congenital spinal deformities, hereditary connective tissue 
disorders leading to weakening of skeletal tendons and ligaments, asymmetrical stress due to 
neuromuscular disorders, and metabolic disorders such as osteogenesis imperfecta [5]. But 
these factors only account for about 15-20% of scoliosis curvatures. Hence, the remaining 
80% is considered to be or idiopathic, without a clear underlying cause. 
 
1.1.6 Treatment: 
 
Treatment of scoliosis mainly depends on the severity of the curve. Observation is 
usually recommended if the degree of the curve is between 10º and 25º. Bracing is adopted if 
the curve is between 30 and 40º. Braces like underarm thoracolumbar-sacral orthosis type 
cannot correct scoliosis, but can prevent the curve progression to a significant level [6]. 
Curves greater than 40-45º require spinal surgery with instrumentation in order to correct the 
scoliosis to a significant extent and stop future progression of curve severity [7]. 
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1.2 Etiology of Adolescent Idiopathic Scoliosis 
 
The etiology of AIS remains obscure, and seems to be multi-factorial in origin without 
a single underlying cause. Extensive research is being done on the possible role of the 
endocrine system, nervous system, and spinal musculature, basic structural elements of the 
spine, environmental factors, and genetics in the pathogenesis of AIS. Unfortunately, most of 
the study findings weren’t convincing enough, and some factors seems to be more of a 
consequence than a cause. In the next section I will talk about factors that have been attributed 
to the development of AIS, including the hormone melatonin and its signaling, genetics and 
other chemical, metabolic factors. 
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1.2.1 Role of Melatonin in AIS etiology: 
Melatonin is an indole synthesized from tryptophan, secreted mainly by the pineal 
gland in mammals and is synchronized to the light-dark cycle, with maximum basal levels in 
the night and low basal levels in the day. Thillard et al in 1959 demonstrated that 
pinealectomy (removal of pineal gland) in chickens resulted in the deformation of the 
vertebral column, which is phenotypically similar to that of human AIS [8]. Since then, 
experimental induction of scoliosis in chickens has been used to study the potential role of 
melatonin in the etiology of AIS [9]. Machida et al experimentally induced scoliosis in 
chickens and rats through pinealectomy, maintaining some rats in bipedal and others in 
quadrupedal state. Interestingly, only bipedal rats developed scoliosis compared to the 
quadrupedal ones. This indicates that bipedal condition like in humans facilitate the 
development of scoliosis after pinealectomy [10]. The importance of melatonin in the etiology 
of scoliosis is further strengthened by another study by the same group wherein scoliosis was 
experimentally induced in C57BL/6J mice, a mouse strain naturally deficient in melatonin, 
through re-sectioning of forelimbs and tail. All the bipedal mice developed scoliosis, whereas 
the bipedal mice that received intraperitoneal melatonin did not develop scoliosis, suggesting 
that melatonin deficiency is an important etiologic factor for AIS. Based on this, Machida et 
al. measured the levels of melatonin in AIS patients with progressive and stable curves and 
observed that the former group had very low levels of melatonin compared to the latter, whose 
levels where similar to the control subjects.  These results strongly suggested a role for 
melatonin in the etiology of scoliosis but was highly controversial as a majority of other 
clinical studies showed that there were no significant difference between the circulating levels 
of melatonin in AIS when compared to control subjects [11], and experimental pinealectomy 
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did not give rise to scoliosis [12], in non human primates, suggesting that melatonin deficiency 
leads to scoliosis only in smaller animals and not in humans [13].  
In that context, Moreau et al. postulated that the real culprit was not a deficiency of 
melatonin but rather a melatonin signaling dysfunction in AIS [14]. They tested the ability of 
osteoblasts obtained from AIS patients and healthy controls to inhibit accumulation of 
forskoline induced cAMP.  They observed that osteoblasts of AIS patients had higher levels of 
cAMP compared to controls, which suggested that the melatonin signaling pathway was 
somehow impaired in AIS patients at varying degrees.  The cAMP assay led to the functional 
classification of AIS patients into three functional groups based on their responsiveness to 
melatonin and cAMP levels (Figure 1.1). Using a non hydrolyzable GTP analogue Gpp(NH)p, 
they demonstrated that the melatonin signaling dysfunction can be caused by a reduced 
functionality of Gi proteins, in AIS patients. They experimentally ruled out the possibility of 
involvement of melatonin receptors, which was in agreement with previous studies showing 
no specific association of mutations found in MT1 or MT2 melatonin receptor [15]. By far this 
is the most convincing evidence for melatonin's role in pathogenesis of AIS and the presence 
of three distinct functional groups in AIS strongly argues in favor of more than one gene 
involved in this condition. 
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Figure 1.1: A. Melatonin signal transduction. Melatonin binds to its G protein coupled 
receptors (GPCR) MT1 or MT2 and inhibits the accumulation of cAMP via Gi subunits. B. 
Analysis of melatonin inhibition of adenylyl cyclase activity in human osteoblasts derived 
from AIS and control subjects. The graph shows the inhibition of forskolin-induced cAMP by 
increasing melatonin concentrations, from -11M to -5M. The patients are classified into three 
functional groups based on the percentage of cAMP inhibition by melatonin. Adopted from 
[16] 
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1.2.2 Genetic factors  
Clinical and population studies demonstrated a greater incidence of scoliosis among 
individuals who were closely related to scoliotic patients, compared to the general population 
[17]. Harrington et al found that there was a 27% incidence of scoliosis in daughters of women 
affected by scoliosis greater than 15º [18]. Studies conducted in twins showed a high 
concordance rate (75%) of idiopathic scoliosis in monozygotic twins, compared to dizygotic 
twins (36%) [19]. Taken together, these results show that idiopathic scoliosis can be a genetic 
disorder.  
 
Even though there is an increase in evidence of the genetic nature of scoliosis, its mode 
of inheritance still remains obscure. Studies conducted by Wynne-Davies et al concluded that 
the disease is hereditary and have a dominant and multiple-gene pattern of inheritance [17]. 
Riseborough’s study on 2869 individuals concluded that a multi-factorial mode of inheritance 
maybe involved [20]. Work by Cowell et al, suggested that idiopathic scoliosis has an X-
linked dominant inheritance pattern [21]. 
 
More recently, many researchers have used genome-wide linkage analysis studies to 
identify specific genetic loci associated with the occurrence of idiopathic scoliosis in a variety 
of populations. Several putative regions have been identified till to date, including four regions 
on chromosomes 3, 6, 10, and 19 the latter being the most significant [22, 23]. Genome wide 
scan based on the mode of inheritance showed that the group with a potential X-linked mode 
of inheritance showed a link between the disease and a region on the X-chromosome, in a few 
families [24]. 
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1.2.3 Other Factors: 
Apart from melatonin signaling dysfunction and genetic factors, researchers postulated 
that adolescent idiopathic scoliosis may be caused by abnormalities in the structural elements 
of the spine, neurological disorders, chemical and metabolic factors, hormones, etc.  
 
The most striking characteristic of AIS is a severe deformity of the spine with wedging 
of vertebrae and an extensively deformed inter-vertebral disc. Taking this as a cue, several 
studies investigated the possible role of structural elements of spine and its metabolic aspects 
in etiology of idiopathic scoliosis (IS). Inter-vertebral disc is made of annulus fibrosus 
enclosing a nucleus pulposus, which contain collagen and proteoglycans. IS nucleus pulposus 
showed an increase in collagen and a decrease in glycosaminoglycan levels, which supposedly 
lead to an increased degradation, [25], but later they were proven to be secondary due to the 
high pressure exerted on the inter-vertebral disc by the deformed vertebrae [26]. 
 
Apart from hormonal, genetic, structural and chemical factors, the central nervous 
system has also been a target of detailed investigation for its possible role in IS pathogenesis. 
Earlier studies indicated an incidence of scoliosis in animals exposed to experimental 
medullary damage [27], excision of dorsal spinal nerve roots [28], destruction of brain stem, 
posterior hypothalamus and the postural reflex system [29].  
 
However, in spite of all the promising research in a wide variety of fields, the etiology 
of AIS still evade being unraveled and still remain a true multi-factorial entity.  
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1.3 Hypothesis 1 
 
The first hypothesis for our study is primarily based on evidence from earlier research 
using Pitx1 knockout mouse model.  
1. Pitx1 +/- mice were phenotypically normal and fertile at birth, but developed severe 
spinal deformity around two months after birth.  
2. The Pitx1+/- phenotype is strikingly similar to that found in AIS patients (Figure 1.2). 
3. Moreover, individuals diagnosed with AIS are normal at birth without any congenital 
malformations, but later develop scoliosis, during the onset of puberty. This somewhat 
mirrors the onset of scoliosis in Pitx1+/- mice. 
Based on the above listed observations, we postulated that Pitx1, a homeo-box 
containing transcription factor maybe involved in the patho-mechanism leading to the 
development of AIS in Humans. 
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Pitx1+/- Human
 
 
 
Figure 1.2: Radiographs of Pitx1+/- mouse and a Human with adolescent idiopathic 
scoliosis. Pitx1+/- mice develop scoliosis after 2-4 months of being born. Humans develop AIS 
during the onset of puberty. 
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1.3.1 Pitx1 
PITX1 is the pituitary transcription factor, which belongs to the PITX family 
containing two other members Pitx2 and Pitx3 (Figure 1.3). They are members of a paired 
class of homeo domain transcription factors. Pitx1 codes for a protein of 315 amino acids long 
and have a characteristic homeo domain containing three  helices and an N terminal arm 
involved in protein-protein interactions and influences binding specificity via a lysine 49 
residue within the homeodomain [30].  Pitx1 can induce or prevent transcription of target 
genes by binding as a monomer to a TAATCC sequence within target promoters [31]. This 
binding site is recognized by its family members and is highly conserved from Drosophila to 
Humans.  
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Figure 1.3: Vertebral Pitx1 paralogues. The black region represents the homeodomain, and 
the grey region represents the OAR region (located next to the C-terminus, with the ability to 
inhibit the protein’s DNA binding activity), which is highly conserved in Drosophila and 
vertebrates. The numbers show percentage similarity between domains of paralogues with 
respect to Pitx1. (Adapted from [32]). 
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1.3.1.1 Role of Pitx1 in development 
PITX1 plays an important role in development and function of organs through unique 
expression pattern. It is expressed in the brachial arches, eye, pituitary, forebrain, midbrain, 
teeth, heart, forelimb mesenchyme and the hindlimb mesenchyme [33].  In addition, it is 
expressed in the olfactory system, posterior lateral plate mesoderm, bladder, stomach, 
pancreas etc. PITX1 shows specific expression in the posterior limbs, and is involved in the 
patterning of hindlimb and mandible development.  In in situ hybridization studies on whole 
mount mouse embryos, Pitx1 was first detected at E9.5 in the first brachial arches, and at the 
posterior region corresponding to future hindlimb buds. Its expression intensifies in the 
hindlimb buds and mandibular arches at E10.5, but is absent in the forelimb buds. Continued 
expression of Pitx1 in the proximal region of hindlimb and mandibular arches is observed at 
E11.5 through E13.5 during which it is observed in the Rathke’s pouch, tongue and genital 
eminence [34]. Targeted inactivation of PITX1 in mouse leads to severe hindlimb and 
craniofacial malformations. Pitx1 -/- mice died at birth and showed severe impairment of bone 
development in their hindlimbs and mandibles (Figure 1.4), thereby confirming the 
importance of Pitx1 in skeletal development [35]. 
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Pituitary gland
Hindlimb
Pitx1 +/- Pitx1 -/-
 
Figure 1.4: The role of Pitx1 in development. A. Important Pitx1 expression sites in a 
developing embryo include the hindlimb mesenchyme, pituitary, branchial arches, palate and 
teeth. (Adopted from [32]). B. Skeletal preparation of Pitx1+/- and Pitx1-/- new born pups. 
Pitx1-/- new born (right) exhibits severe craniofacial and limb malformations (Adopted from 
[35]). 
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1.3.1.2 Pitx1 in the pituitary: 
Involvement of Pitx1 in the function of anterior pituitary gland is well studied. There 
are six types of hormone producing cells in the pituitary gland.  The cell type that expresses 
the pro-opiomelanocortin (POMC) is the first to differentiate. Lamonerie et al identified Pitx1 
as a novel protein that regulated the expression of POMC in the anterior pituitary lobe. Hence, 
PITX1 binds to the target site within the promoter of POMC and regulates its transcription in 
corticotroph cells, thereby playing a role in pituitary gland formation [31]. In addition, Pitx1 
acts synergistically with other pituitary specific transcription factors (Table 1.1) to promote 
gene expression, which leads to specific cell phenotypes in the anterior pituitary [36]. 
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Table 1.1: Table shows the various co factors with which Pitx1 acts synergistically to regulate 
target promoters in the pituitary gland.  
 
 
Gino poulin 2000
Tremblay 1998
Tremblay 1998
Tremblay 1998
References
SomatolactotrophsPituitary glandPRLPit1
CorticotropesPituitary glandPOMCNeuroD1
GonadotropesPituitary gland-LHSF-1
CorticotropesPituitary glandPOMCTpit
Cell typeOrganTarget promoterPitx1 cofactors
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1.3.1.3 The role of Pitx1 in limb development: 
In the developing mouse embryo, Pitx1 is mainly expressed in the developing hindlimb [33], 
the first branchial arch and the anterior pituitary [37], and very less expressed in the forelimbs 
[34]. Pitx1 is required for the establishment of hindlimb and forelimb identity. Szeto et al., 
studied the importance of Pitx1 in limb development using Pitx1-/- mice. They observed that 
proper development of hindlimb, first branchial arch and anterior pituitary was compromised 
in the Pitx1-/- mouse strain. Moreover, the skeletal structures of the hindlimb like tibia and 
fibula were significantly reduced in length and had morphology similar to the corresponding 
structures of the forelimb. Furthermore, the expression of Tbx4, a downstream target gene of 
Pitx1 and marker of hindlimb specificity was reduced in Pitx1-/- hindlimbs.  
 
The ectopic expression of Pitx1 in the chicken wing resulted in its abnormal growth and 
patterning leading to the straightening out of the curved wing structure, alterations in length 
and number of digits, characteristic of hindlimb patterning [38]. All these data suggests an 
evolutionarily conserved role of Pitx1 gene in limb specificity among vertebrates. 
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1.3.2 Importance of Pitx1 in human disease: 
1.3.2.1 Pitx1 and osteoarthritis: 
Pitx1 plays an important role in chondrogenesis during development. Partial 
inactivation of Pitx1 in mouse (Pitx1+/-) leads to the formation of osteoarthritis like phenotype, 
characterized by abnormal thickening of subchondral, trabecular and cortical bone, and 
increased calcification of the cartilage. Based on this evidence, Picard et al. investigated the 
role of Pitx1 in human osteoarthritis [39]. In human OA articular chondrocytes, Pitx1 was 
hardly detected at the mRNA levels, compared to that of human control subjects. In addition, 
histological sections of human OA cartilage showed a decrease in Pitx1 proteins, while the 
normal cartilage still retained the expression. Picard et al. demonstrated a loss of Pitx1 in 
human primary knee joint in OA, suggesting a role for this transcription factor in the 
pathogenesis of osteoarthritis in humans. 
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1.3.2.2 Role of Pitx1 in the etiology of Clubfoot: 
Clubfoot is an autosomal dominant, congenital limb malformation, with an incomplete 
penetrance that affects 1 child in 1000 births with a male to female ratio of 2:1 [40],[41]. 80% 
of clubfeet cases are idiopathic [42]. Gurnett et al identified Pitx1 as the gene responsible for 
clubfoot through genome-wide linkage analysis of 13 members of a family affected with the 
malformation using Affymetrix 10K mapping data. A 12Mb candidate region on chromosome 
5q23.3-q31.2 was identified. Pitx1 lies within this candidate region, and a sequence analysis 
showed a G to A substitution, which resulted in the replacement of lysine with glutamic acid 
at position 130 (E130K) within the homeodomain, which is highly conserved. This mutation 
was detected in all the affected individuals tested, compared to five hundred test subjects. The 
glutamic acid is conserved in Pitx1, Pitx2 and Pitx3, and its substitution leads to reduced 
transcriptional activity at least in Pitx1, proven using transfection assays. Moreover, the 
mutant Pitx1 acts a dominant negative inhibitor of Pitx1 transactivation [43]. Since Pitx1 is an 
important transcription factor for hindlimb development, the E130K mutation could be one of 
the links in the Pitx1 pathway leading to Clubfoot. 
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1.3.2.3 Role of Pitx1 in autism: 
Autism represents a spectrum of behavioral disorders characterized by reduced social 
interaction and communication skills, and abnormal behavior. It is known to affect more boys 
than girls, a ratio of 4:1 [44]. To date, no specific cause for autism has been described. It is 
believed to be a genetic disorder, and studies conducted in monozygotic twins [45] as well as 
discovery of nucleotide polymorphisms in genes like neuroligin 3 and 4 suggests that it’s a 
complex, multi-gene disorder [46]. 
 
Through genome-wide linkage analysis in 276 affected families, Philippi et al identified a 1.2 
megabase region on chromosome 5q31, which had a strong association. This region harbors 
three genes, Pitx1, neurogenin 1 (involved in neurogenesis) and histone family member Y 
(H2AFY). Single point association analyses ruled out the last two, and showed a significant 
association of Pitx1 with autism, Haplotype analysis revealed that individuals with an A-C 
haplotype risk allele were 2.54 and 1.59 fold respectively, susceptible to autism. This might 
explain the abnormal levels of POMC (pro-opio-melanocortin) and adrenocorticotropin 
(ACTH) in autistic patients suggesting a gain of Pitx1 expression, since these hormonal genes 
lie downstream of Pitx1 [31]. More studies need to be done to understand the exact 
mechanism through which Pitx1 contributes to autism etiology.  
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1.3.2.4 Pitx1 and Cancers: 
Activation of RAS pathway is a significant contribution to tumor pathogenesis. RAS is 
a small GTPase which is activated by GTP exchange factors and attenuated by GTPase 
activating proteins (GAP). Although mutations leading to the gain of function of RAS are 
often attributed to tumorigenesis, wild type RAS genotypes also can enhance the phenomenon 
due to the activation of their pathway via the inhibition of a tumor suppressor.  
 
Pitx1 is known to be often downregulated in various cancers (Table 1.2) including 
colon cancer where it is associated with levels of wild type RAS expression. Kolfschoten et al. 
used RNAi screening strategy on immortalized fibroblast cell line which only require 
knockdown of a single tumor suppressor for its transformation. They identified Pitx1 to be 
knocked down resulting in the transformation of cells. The phenotype of Pitx1kd cells was 
found to be strikingly similar to those over-expressing RAS. They also looked at potential 
RAS GTP-activating factors that could inhibit RAS activity, and found RASAL1 to be 
transcriptionally activated by Pitx1 (Figure 1.5). Inhibition of RASAL1 resulted in cell 
phenotype similar to that of Pitx1kd cells. Hence, they concluded that the role of Pitx1 as a 
tumor suppressor comprises of activating RASAL1, a RAS-GTPase activating protein which 
inhibits RAS activity and tumorigenicity [47].  
 
Further evidence for the tumor suppressor activity of Pitx1 is gradually surfacing in 
other types of cancer. DX Liu et al. analyzed its influence on the transcriptional activity of 
p53, a potent tumor suppressor that influences programmed cell death and apoptosis. Forced 
expression of hPitx1 in human mammary carcinoma cells (MCF-7) increased the mRNA and 
protein levels of p53, resulting in 91% apoptosis after third day of transfection [48]. Two Pitx1 
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consensus elements were found on the promoter of p53, and transient over-expression of Pitx1 
showed an increase in expression levels of p53 and its direct downstream targets p21 (G1 and 
G2/M phase arrest) [49] and PTGF (G1 cell cycle arrest and apoptosis) [50]. This was further 
confirmed by siRNA depletion of Pitx1, which led to a decrease in their basal expression. 
Taken together, these data suggest an emerging role for Pitx1 as a tumor suppressor. 
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Figure 1.5: Pitx1 mediated inhibition of RAS. A pathway showing how pitx1 mediates the 
repression of RAS through the activation of RASAL1, a RAS-GTPase activating protein, 
thereby controlling the transformation activity by RAS. 
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Table 1.2:  List of various types of cancers where downregulation of Pitx1 occurs. 
 
 
Ramaswamy, S. et al., 2001Bladder cells carcinoma
Huang, Y.D. et al., 2007Lingual squamous cell carcinoma
Lord, R.V. et al., 2005
Barrett’s esophagus and Barett’s  
associated adenocarcinoma
Singh, D. et al., 2002Prostrate cancer
Chen, Y.N. et al., 2008Human gastric cancer
Chen,Y. et al., 2007Human lung cancer
StudyCancer Type 
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1.4 Hypothesis 2  
 
We postulate that hypoxia, is involved in the regulation of transcription factor Pitx1, 
which could contribute towards AIS pathogenesis. Our hypothesis is based on the following 
studies: 
1.  Sonna et al used the powerful DNA micro array technology to study the effect of 
hypoxia exposure on human hepatocytes (HepG2) [53]. They analyzed the mRNA 
expression levels using Affymetrix Gene Chip arrays consisting of approximately 
12600 sequences. Apart from the known hypoxic responsive genes being up regulated, 
they found a down regulation of a number of genes involved in cell adhesion, cell 
growth, differentiation and proliferation, membrane transport, metabolism and 
biosynthesis. Interestingly, their experiments showed a significant down regulation of 
our gene of interest Pitx1. 
2. Rivard et al., in 1986 conducted a study wherein pregnant mice were exposed to 
hypoxia for 5 hours at 9.5 days of pregnancy. The 9.5th day is significant for the proper 
development of the somites to form the precursor of spine. They were able to induce 
spinal deformity in 90% of the pups that underwent maternal hypoxic treatment, which 
is similar to the phenotype found in human. This study showed that hypoxia is a 
powerful agent that can influence normal segmentation and vertebrae structure [51]. 
3. In a similar study, Loder et al., exposed pregnant mice at 9.5th day of pregnancy  to 7 
hours of hypoxia (660 ppm CO), which induced congenital deformities in the cervical, 
thoracic and lumbar regions of the spine in  77% of progeny. They found that 
deformities were directly proportional to increase in hypoxia [52].  
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Points 2 and 3 clearly show that hypoxia is a potent inducer of severe spinal deformities in 
mice, which raises our curiosity in analyzing whether this stress can contribute towards the 
development of AIS in Humans. Moreover, the fact that hypoxia can down regulate Pitx1 
expression in human cells led us to hypothetically establish a link between hypoxia, Pitx1 and 
AIS pathogenesis. 
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1.5 Hypoxia and Hypoxia inducible factors 
Oxygen is very important for the survival of most living organisms. Since a sharp 
decrease in oxygen levels (hypoxia) would prove fatal, there evolved a complex oxygen 
sensing mechanism that triggers activation/deactivation of various genes to survive and adapt 
to the hypoxic stress. The hypoxia response pathway is well studied as it plays crucial role in 
development and cancer. A well-studied example for this would be the activation of 
Erythropoietin gene by hypoxia in humans and mice [54-56]. Erythropoietin is a hypoxia-
inducible cytokine made of 165 amino acids. During hypoxic stress, erythropoietin gene gets 
activated, which induces erythropoiesis by stimulating proliferation and differentiation of 
erythroid progenitor cells leading to increased oxygenation of the hypoxic tissue. Thus, 
erythropoietin induction is a defensive response, which promotes oxygen supply to areas 
affected by hypoxia [57]. 
1.5.1 Hypoxia Inducible Factors (HIFs): 
It was while investigating the molecular mechanisms responsible for the regulation of 
Erythropoietin gene (EPO) by hypoxia that Beck et al. discovered a cis-acting hypoxia 
response element (HRE) in the 3’ flanking region to the EPO gene [56]. Subsequently, 
Semenza et al. identified the proteins that bound the HRE on EPO gene using DNA affinity 
chromatography [58]. One of them was a novel protein subunit designated Hypoxia Inducible 
Factor-1 (HIF-1) and a previously known  subunit called HIF-1 [59]. HIF- family 
consists of three  subunits: HIF-1, HIF-2 and HIF-3 (Figure 1.6). The expression of these 
 subunits are elevated during hypoxia and tightly controlled during normoxia. The  subunit 
HIF- is a constitutively expressed protein in the nucleus independent of oxygen levels and is 
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also known as aryl hydrocarbon receptor nuclear translocator, or ARNT. It exists in three 
isoforms, ARNT1, ARNT2 and MOP3 (Member of Pas Protein 3). 
Hypoxia Inducible Factor  is a heterodimeric transcription factor consisting of a  and  
subunits, which are two basic helix-loop-helix (bHLH) and PER-ARNT-SIM (PAS) domain 
proteins [60]. The HIF- subunit is highly regulated via a proteosomal degradation pathway 
under normoxia conditions, whereas it exhibits higher stability and transcriptional activity 
under hypoxia. It is 826 amino acids long, contains bHLH and PAS domains for dimerization 
with the  subunit and DNA binding. The Oxygen Dependent Degradation Domain (ODDD) 
regulates the stability of HIF-1 [61]. It also contains two Transactivation Domains (TAD), N-
TAD and C-TAD. 
HIF-2 , widely known as EPAS-1 (Endothelial PAS protein-1) was first identified 
through a homology search against HIF-1 . It is also known as HLF (HIF-like factor), HRF 
(HIF related factor) and MOP2 (Member of PAS super family 2). Like HIF-1, it contains an 
ODDD, and is induced by hypoxia and regulates target genes by binding to their hypoxia 
response elements as a heterodimer. It is also degraded by the same proteosomal degradation 
pathway. Even though it shares high homology in the DNA binding domain with HIF-1, 
there is less redundancy in their functions or target genes, which explains why HIF-1-/- and 
HIF-2-/- mouse knockout models showed completely different types of phenotype. HIF-1-/- 
mice show poor vascular and cardiac development and embryonic lethality, whereas HIF-2-/- 
embryos exhibit more refined vascular defects, lethality due to multi-organ failure and 
aberrant mitochondrial function. In addition, in human cancers, poor prognostic outcomes are 
more associated with over expression of HIF-2 than HIF-1. 
The third member of the HIF- family is HIF-3, also known as MOP7. There are 
multiple variants namely, HIF-3 alpha 1 to 6. Interestingly, the HIF-3 subunit is known to 
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inhibit HIF-1 by binding to it, resulting in the inhibition of HIF-1 target genes like VEGF. 
The splice variants HIF-3  1 to 3 are regulated and degraded by the same pathways of HIF-1 
and HIF-2 [62]. 
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bHLH PAS ODDD
NTAD CTAD
80% 70% 77%
69% 67% 57%
68% 65% 63%
HIF-1
HIF-2
HIF-3
 
 
Figure 1.6: Comparison of various domains between the three hypoxia inducible 
transcription factors, HIF-1, HIF-2 and HIF-3. The numbers show the percentage of 
similarity between the domains. bHLH: basic helix loop helix, PAS: Per-Arnt-SIM domain, 
ODDD: oxygen dependent degradation domain, NTAD: N terminal transactivation domain, 
CTAD: C terminal transactivation domain.  
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1.5.2 Regulation of HIFs:  
HIF-1 is sometimes called the master commander of cellular oxygen response 
pathway. Its induction is very important for the viability of cells faced with hypoxia. Both 
HIF-1 and HIF-1 are expressed at the mRNA levels in normoxia conditions, but at the 
protein level, HIF-1 becomes undetectable in cells. This is because of an oxygen dependent 
degradation of HIF-1 protein in the cytoplasm through a proteosomal degradation pathway. 
This degradation is made possible by oxygen sensing enzymes called HIF Prolyl Hydroxylases 
Domain Proteins (PHDs) which requires oxygen, Fe2+, 2-oxoglutarate and ascorbate for their 
activity [63]. There are three isoforms of PHDs, namely PHD1, PHD2 and PHD3 capable of 
hydroxylating HIF-1, but PHD2 shows the highest activity [64]. 
 
1.5.2.1 Oxygen dependant regulation of HIF-1 and HIF-2  protein:  
Under normoxia, PHD hydroxylates two proline residues Pro402 and Pro564 in the 
Oxygen Dependent Degradation Domain (ODDD) of HIF-1 [65]. The modified residues are 
then recognized and bound by von Hippel-Lindau (VHL) tumor suppressor protein, a 
component of the E3 ubiquitin protein ligase, which makes HIF-1 a target for proteosomal 
degradation. Inactivating mutations in VHL was shown to result in the accumulation of HIF-
1, even under normoxia [66]. 
 
 Another oxygen dependant hydroxylase called Factor Inhibiting HIF-1 (FIH-1) 
provides a second-level of “security” if any HIF-1 somehow escapes degradation and 
accumulates in the cell [67]. It is an asparaginyl hydroxylase that modifies ASN803 in the C-
terminus TAD of HIF-1. This disrupts the hydrophobic interface dependent interaction 
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between C-TAD of HIF-1 and the CH1 domain of its co- activator P300/CBP, leading to 
inhibition of its transactivation [68].  
Another post transcriptional modification apart from hydroxylation brings about 
degradation of HIF- under normoxia. The Arrest-Defective-1 protein (ARD1), member of the 
super family of acetyltransferases, acetylates Lys532 in the ODDD of HIF-1. This results in 
the binding of VHL to HIF-1 and its subsequent degradation by the proteosomal pathway 
[69]. 
1.5.2.2 Oxygen Independent regulation of HIFs 
Apart from being regulated via oxygen dependent mechanisms like hypoxia, HIF- has 
been shown to be activated by growth factor signaling, loss of tumor suppressor genes like 
VHL and PTEN, as well as gain of function mutations in oncogenes that can trigger the 
Mitogen-activated Protein Kinase (MAPK), Phosphatidylinositol 3-Kinase (PI3K) and the 
SRC signal transduction pathways. Recent studies have shown that HIF-1 can be activated in 
normoxic cells by Insulin [70] and Insulin-like growth factors [71], Tumor Necrosis Factor  
(TNF-) and Interleukin-1 (IL-1) [72], angiotensin II [73] , and thrombin [74]. 
 
An excellent example for the oxygen independent regulation of HIF- would be the 
process of its stimulation by growth factors via the activation of MAPK pathway [75]. Binding 
of a growth factor to its specific membrane receptor results in the activation of ERK1/2 by an 
upstream MAP/ERK kinase, MEK. ERK then activates MNK (MAP kinase-interacting 
kinases). Meanwhile, ERK also phosphorylates the P70 S6 kinase (S6K), which then 
phosphorylates the ribosomal S6 protein and the eukaryotic translation initiation factor 4E 
(eIF-4E) binding protein (4E-BP1). Normally, binding of 4E-BP1 to eIF-4E prevents cap-
dependent translation of mRNAs in cells, but its phosphorylation by ERK inhibits this activity. 
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Meanwhile, MNK phosphorylates and activates eIF-4E, which results in cap-dependent 
translation of mRNAs into proteins including HIF-, in response to growth factor signaling.  
 
In addition, current studies have demonstrated that MAPK signal transduction pathway 
up regulates HIF-1 activity, by encouraging the formation HIF-p300/CBP transcription 
complex, by modulating the transactivation of p300/CBP [75]. While oxygen dependent 
activation and regulation of HIF-1 happens in all cell types, growth factor mediated (oxygen-
independent) regulation of HIF-1 is cell-type specific. 
1.5.3 HIF- activation: The classic hypoxia response pathway: 
As mentioned earlier, under normoxia, two prolyl residues (Pro 402 and Pro 564) in 
the ODDD of HIF-1 are modified and leads to VHL-mediated proteosomal degradation of 
the protein.  Hydroxylation of HIF- requires oxygen, 2-oxoglutarate and Fe (II) as substrates. 
Hence during hypoxia, there would be a considerable shortage of these substrates, which 
would limit the activity of these hydroxylases. Thus, prolyl and asparaginyl (by oxygen 
dependent FIH-1 hydroxylase) hydroxylation is inhibited, and VHL cannot recognize and bind 
to HIF- for its proteosomal degradation. This leads to the accumulation of HIF- protein, 
which translocates into the nucleus. It forms a heterodimer with its -subunit HIF- and along 
with its transcriptional co-activators p300/CBP [76], binds to hypoxia response elements 
(HRE) within promoters of its target genes and induces their expression.  
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1.5.3.1 Targets of HIF-Hypoxia Response pathway. 
Hypoxia and HIFs are known to control important genes involved in transcriptional 
regulation, angiogenesis, erythropoiesis, vasodilation, glucose metabolism, cell proliferation, 
cell survival, apoptosis, epithelial homeostasis and many more (Figure 1.8). Here is a well 
studied example. 
Vascular endothelial growth factor (VEGF) is a cytokine whose expression is induced 
by HIF-1 during hypoxia. It signals to hematopoietic stem cells and endothelial progenitor 
cells to form new blood vessels at the site of an injury or stress thereby promoting 
angiogenesis. The induction of VEGF by HIF-1/HIF-1 occurs through the HRE 
(TACGTGGG) within the VEGF promoter in response to hypoxic stress. Hypoxia-induced 
expression of VEGF is critical for the development of new blood vessels during embryonic 
development and enhanced blood supply to solid tumors. VEGF can be directly activated by 
hypoxia, or by certain growth factor stimuli which triggers MAPK or PI3K signaling pathway, 
activating HIF-1 leading to VEGF transcription.  
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Figure 1.7: A schematic diagram showing the various targets of the hypoxia inducible 
factors HIF-1 and HIF-2. Both hypoxic factors are involved in the regulation of important 
physiological processes including angiogenesis, apoptosis and energy metabolism. 
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1.5.4 HIFs and Cancer 
Hypoxia is one of the well studied characteristics of most common human cancers 
[77]. Occurrence of hypoxia results in release of cytokines which promote vascularization, 
leading to progression of tumor growth and metastasis. Growing primary tumors need to 
establish new blood vessels to sustain their growth, hence a combination of hypoxic conditions 
and loss and gain of function of various tumor suppressor genes and oncogenes respectively 
promote over-expression of VEGF in a HIF- dependent manner. 
 
A relevant example for the involvement of HIF-1 in tumor severity would be 
Glioblastoma Multiforme (GBM), the most malignant of cancers with a patient survival rate 
less than 12 months and highly resistant to radiotherapy and chemotherapy [78]. The tumor 
cells rapidly proliferate exceeding their limited blood supply, resulting in necrosis. The 
surviving tumor cells surrounding the region of necrosis over express HIF-1 protein and 
VEGF mRNA [77]. This example shows a correlation between hypoxic condition within the 
tumor, induction of HIF-1 and VEGF over expression, and vascularization, and ultimately 
enhanced tumor growth and progression. 
 
In certain forms of cancer, the over expression of HIF-1 protein and VEGF mRNA is 
not due to hypoxic conditions, but due to loss of function of important tumor-suppressor 
genes. Hemangioblastoma, a form of brain tumor is well characterized by extensive 
vascularization. As expected, it showed very high levels of VEGF mRNA and HIF-1 protein, 
but surprisingly not induced by hypoxic condition. Further analysis revealed a loss of function 
of the von-Hippel Lindau (VHL) tumor suppressor [79]. Under normal circumstances, VHL 
targets HIF-1 protein for proteosomal degradation, but its inactivation in this type of cancer 
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leads to the over-expression of its target, resulting in extremely high levels of VEGF mRNA, 
extensive vascularization and increased tumor survival. 
Gain of function mutations in oncogenes is another deciding factor in tumor incidence 
and progression. Activation of RAS in human cancers switches on the MAPK pathway, 
resulting in the phosphorylation of HIF-1. This increases its transcriptional activity, by 
encouraging the formation of HIF-1/p300 transcriptional complex which then activate genes 
like VEGF, to promote vascularization in tumors and their subsequent progression. 
Enhanced expression levels of HIF-2 are a characteristic feature of colo-rectal, non-small cell 
lung, and head and neck cancer [80]. It is also an indicator of poor prognosis outcome.  
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Chapter 2. Materials and Methods 
2.1 Materials: 
All AIS bone biopsies were collected during spinal surgery after obtaining parents’ signature 
on a consent form approved by the ethics committee of Sainte-Justine University Hospital. 
Each AIS case was clinically assessed by orthopedic surgeons at the hospital. Table 2.1 and 
2.1.1 contains clinical data for each patient. Details about heredity were obtained by 
questioning patients and their family. 
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Table 2.1 Clinical data of Adolescent Idiopathic Scoliosis patients 
Case Gender Age Curve type Cobb angle 
 
 
Heredity 
1137 f 20.5 Double scoliosis 65-42 No 
1167 m 14.5 Left thoracic 49 No 
1045 f 19.4 Left thoracolumbar 38 No 
1007 m 18.6 Right thoracolumbar 61 Mother 
1006 f 12.6 Double scoliosis 61-46 No 
1325 f 16.1 Left thoracic 44 Paternal grandmother 
1322 f 13.1 Double scoliosis 51 No 
1311 f 14.6 Double scoliosis 78 Mother 
1263 f 13.3 Double scoliosis 53 No 
1349 f 11.6 Left thoracolumbar 74 No 
1274 f 13.2 Double scoliosis 42 No 
1277 f 12.7 Double scoliosis 57-48 No 
1276 f 15,2 Left thoracolumbar 42 No 
1266 m 15.5 Double scoliosis 52 No 
1280 f 14.4 Double scoliosis 56-46 No 
1402 f 15.8 Right thoracic 51 No 
1066 f 17.0 Right thoracic 53 Aunt 
1439 f nd Right thoracic 69 Mother 
1425 f 13.4 Right thoracic 68 Mother, maternal grandmother 
1395 f 17.7 Left thoracolumbar 84 Aunt 
1385 f 16.0 Double scoliosis 42-23 No 
1391 f 15.0 Left lumbar 54 No 
1409 f 13.6 Right thoracic 40 No 
1417 f 13.2 Right thoracic 59 
Maternal grand mother, son of cousin from 
father's side. 
1410 f 13.7 Right thoracic 56 nd 
1337 f 14.1 Double scoliosis 57-48 Father's side 
1390 f 15.6 Left thoracolumbar 53 No 
1406 f 14.8 Double scoliosis 62-60 No 
1352 f 7.8 Right thoracic 51 No 
1420 f 13.4 Double scoliosis 60-48 Maternal aunt and younger sister 
1418 f 13.0 Right thoracic 41 No 
1422 f 12.4 Double scoliosis 60-50 Sister 
1360 f 9.9 Double scoliosis 53-46 Father, maternal aunt 
1442 f 13.0 Right thoracic 60 No 
1310 f 15.5 Double scoliosis 55-42 No 
1318 f 13.7 Left thoracolumbar 49 No 
1308 f 15.3 Double scoliosis 77-20 No 
1294 f 16.9 Left thoracic nd Mother 
1306 f 13.1 Double scoliosis 77-48 Mother, maternal grand uncle 
1315 f 14.6 Right thoracic 91 No 
1317 f 13.9 Right thoracic 53 Older sister 
1329 m 14.0 Right thoracolumbar 61 Mother 
1335 f 17.6 Double scoliosis 47-50 No 
1339 f 14.2 Right thoracic 31 No 
1347 f 18.5 Double scoliosis 56-45 No 
1346 f 13.5 Double scoliosis 50-34 Mother 
nd = no data available 
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Table 2.2 Clinical data of control subjects 
 
Case Gender Age Curve type cobb angle Heredity 
1293* m 11.7 Left lumbar 38 No 
1375* f 13.7 Right thoracolumbar 53 Cousin from father's side 
1285* f 15.8 nd 72 Cousins, mother side 
1436* f 13.9 Cyphose 120 No 
1341* f 11.1 Double scoliosis 61-65 No 
1434* f 12.4 Double scoliosis 79-77 No 
1431* m 19.1 Double thoracic 90-90 No 
C100 f nd none none none 
C101 nd nd none none none 
C102 f 18.0 none none none 
C103 nd Nd none none none 
C104 f 14.0 none none none 
C105 f 11.0 none none none 
C106 m 12.0 none none none 
C107 f 13.0 none none none 
C108 f 12.0 none none none 
C109 m 14.0 none none none 
C110 m 15.0 none none none 
C111 m 14.0 none none none 
C112 f 11.0 none none none 
C113 m 14.0 none none none 
C114 nd nd none none none 
C115 m 17.0 none none none 
C116 m 12.0 none none none 
C117 m 16.0 none none none 
C118 m 12.0 none none none 
C119 f 15.0 none none none 
C120 f 15.0 none none none 
C121 f 8.0 none none none 
* Non AIS: samples from patients with other types of scoliosis; C100 to C121: samples from non scoliotic, healthy subjects who 
underwent treatment for trauma. nd= no data available. 
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2.2 Methods: 
2.2.1 Cell Culture of human osteoblasts 
AIS bone specimens obtained from spinal surgery (Table 2.1) were reduced to smaller 
pieces and incubated in a 10 cm culture dish (Corning, Life science) containing -MEM 
(Invitrogen, Burlington, ON, Canada) supplemented with 10% Fetal Bovine Serum and 1% 
Penicillin/Streptomycin at 37ºC in 5% CO2 for 30 days. Control bone specimens were 
similarly processed. Once the new osteoblasts derived from the bone fragments reached 
confluence after a proliferation period of around 15 days, they were treated with Trypsin, 
separated from the bone fragments and a primary osteoblast culture established. The cells were 
passed according to requirements, and harvested for RNA extraction and nuclear protein 
extraction. 
2.2.2 Reverse Transcriptase-PCR 
Total RNA from osteoblasts of patients and control subjects was extracted using Trizol 
(Invitrogen, CA, USA). 4μg of RNA was taken to synthesize cDNA using the Thermoscript 
RT-PCR kit (Invitrogen, CA, USA) according to the manufacturer’s protocol. The PCR 
reaction was carried out in a final volume of 50μl containing 0.5μM of forward and reverse 
primers each, 0.2mM dNTP mix, 2mM MgCl2, 1X Taq buffer, 0.5μg cDNA, and 1U of DNA 
Taq polymerase (Invitrogen, Burlington, ON, Canada). The genes Pitx1, and -actin were 
amplified from the cDNA using the following primers and conditions. Pitx1 (501bp) Forward: 
5’-GACCCAGCCAAGAAGAAGAA-3’ Reverse:5’-GAGGTTGTTGATGTTGTTGAGG-3’; 
Primer annealing at 69ºC for 45 seconds, and elongation at 72ºC for 1 minute, 35 cycles. -
actin (233bp) Forward 5'-GGAAATCGTGCGTGACAT-3', Reverse: 5'-
TCATGATGGAGTTGAATGTAGTT-3. Primer annealing at 55ºC for 1 minute, elongation at 
72ºC for 1 minute, 30 cycles.                   
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2.2.3 Preparation of Nuclear Extracts: 
Three 10 cm dishes containing approximately 1X107 osteoblast cells each were washed 
twice, scraped with cold PBS (10.1mM Na2HPO4, 1.8mM KH2P04, 2.7mM KCl, and 137mM 
NaCl, adjusted to pH 7.4). Cells were spun at 0.1xg for five minutes at 4ºC and the resulting 
cell pellets re-suspended in 300μl of hypotonic buffer A (10mM Hepes pH 7.9, 1.5mM 
MgCl2, 10mM KCl, 1% NP40, 0.5mM DTT, and 1X complete EDTA free protease inhibitor 
cocktail ((Roche, IN, USA)). This was incubated on ice for 25 minutes, vortexing at regular 
intervals. Homogenates were then spun at 0.9xg for five minutes at 4ºC to pellet the crude 
nuclear fraction. Both centrifugations were done using Heraeus Fresco 17 centrifuge (Thermo 
Scientific, MA, USA). The supernatant containing the cytosolic proteins was transferred into 
new tubes and spun using the above criteria, to remove residual contaminants from nuclear 
fraction. The crude nuclear fraction was re-suspended in 8ml of Buffer containing 50mM Tris-
HCl pH 7.6, 2mM EDTA, 2mM EGTA, 1mM DTT, 0.1% Triton X-100 and 1X complete 
EDTA free protease inhibitor cocktail (Roche, IN, USA) and layered over a 30% sucrose 
solution made in the above buffer, without triton in 15ml tubes. Samples were centrifuged at 
3716xg for fifty minutes at 4ºC using a Sorvall legend RT plus easy-set centrifuge with a 
swing out rotor (Thermo Scientific, MA, USA). The supernatant was removed, and the pellet 
of pure nuclear proteins was re-suspended in 50-150μl of double distilled water. The protein 
concentration was determined by Bradford assay (Bio-Rad, Hercules, CA, USA). 
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2.2.4 EMSA: 
Double stranded oligo nucleotide 5’-CGACAAACTTCACCTACGTGCAAG-3’ 
containing HIF binding site of Pitx1 promoter was labeled with 32P dCTP and incubated with 
nuclear extracts from patients or controls in a final volume of 20μl reaction mixture containing 
25ng poly( dI-dC) and a suitable 1X binding buffer (5% Glycerol, 20mM HEPES, 0.2mM 
EDTA, 0.2mM EGTA, 100mM KCl, 2mM Dithiothreitol). The whole mixture was incubated 
at room temperature for 45 minutes. For super-shifts, 2g of appropriate antibodies were 
incubated with the reaction mixture on ice for 1 hour. For competitions, 10 fold, 20 fold, 40 
fold and 80 fold of cold double stranded oligo nucleotide containing the consensus HIF 
binding site 5’-TCTGTACGTGACCACACTCACCTC-3' was added to the mixture. The 
DNA-protein complex was separated from the free probe on a 7% non-denaturing 
polyacrylamide gel at 180 V for approximately 4 hour. The gel was dried and exposed to an 
auto radiographic film to visualize the complexes. 
2.2.5 Plasmids: 
4 kb fragment corresponding to the proximal Pitx1 promoter was amplified from 
human genomic DNA and cloned into pGL4 reporter vector (Invitrogen). The HA tagged 
HIF1  pcDNA3 expression vector and ARNT (HIF1 ) pcDNA3 expression vector were kind 
gifts from Dr. Eric Huang (Brigham and Women’s Hospital, Harvard Medical School, Boston, 
MA, USA). 
2.2.6 Cell Culture and Transient transfection: 
MG-63 human osteosarcoma cells were cultured in DMEM containing 10% Fetal 
Bovine Serum (FBS) and 1% Penicillin/Streptomycin (Invitrogen) till they were confluent. 
Osteoblasts derived from AIS and normal subjects were cultured in -MEM with 10% FBS 
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and 1% Penicillin/Streptomycin. Around 150,000 cells/well were plated in 12 well plates with 
DMEM or -MEM supplemented with 10% FBS and 1% Penicillin/Streptomycin 
(Invitrogen), 16 hours prior to transfection. Transfection of cells were done in Opti-MEM I 
reduced serum medium (Invitrogen) using Lipofectamine 2000 reagent (Invitrogen) according 
to standard protocol, with 250ng of reporter plasmid, 250ng of expression plasmids, and 
150ng of -Galactosidase as an internal control. 2 hours after transfection, the Opti-MEM™ I 
reduced serum medium was replaced by 1 ml/well serum-free DMEM or -MEM containing 
1% Penicillin/Streptomycin (Invitrogen), and the cells were incubated overnight at 37ºC. Next 
day the media was replaced with DMEM or -MEM with 10% FBS and incubated for 24 
hours at 37ºC. 
2.2.7 Luciferase and - Galactosidase Assays 
After 24 hours of incubation, the cells were washed with PBS and lysed in 200μl of 1X 
Glo Lysis Buffer (Promega). The cells were collected in eppendorf tubes and spun quickly. 
30μl aliquots of the supernatant were used for Luciferase and -Galactosidase assays. Each 
reaction was measured in triplicate. The total Luciferase activity for control was normalized 
against -Galactosidase activity and taken as 1. The results were expressed as fold-activity 
with respect to the control. 
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Chapter 3. Results: 
 
3.1 Loss of Pitx1 is observed in osteoblasts from AIS subjects: 
 
Previous studies have demonstrated that targeted inactivation of one allele of Pitx1 in 
mice gave rise to severe spinal deformities, which is similar to the phenotype found in patients 
with AIS (Figure 1.2). The Pitx1+/- mice were initially generated in Dr. Jacques Drouin’s 
laboratory, at IRCM, Montreal.  
 
To investigate if Pitx1 have a role in the aetiology of AIS, we analyzed its expression 
in osteoblasts obtained from severely affected AIS patients and non-scoliotic patients (trauma 
cases) using Reverse-Transcriptase PCR. All AIS osteoblasts showed a complete loss of Pitx1 
expression (n=46), while the control subjects still expressed the gene (n=29) (Figure 3.1.A). In 
a related experiment, Pitx1 mRNA levels in AIS and control subjects were quantified using 
Real time PCR. Again, we observed negative levels of Pitx1 expression in AIS while the 
control subjects showed higher levels. (Figure 3.1.B) 
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Figure 3.1: Comparison of Pitx1 expression in AIS and normal osteoblasts. A. A 
representative RT-PCR showing the loss of Pitx1 expression in AIS (n=46) when compared to 
control subjects (n=29) osteoblasts. All AIS samples showed a loss of Pitx1 expression, 
compared to all controls that still retained the expression. -actin expression was taken as an 
internal control. B. Real time PCR showing the levels of Pitx1 obtained with respect to the 
levels of internal control GAPDH. The figure clearly shows a complete loss of Pitx1 
expression in AIS compared to the control. Statistical analysis using unpaired t-test gave a 
value P<0.0048 (Control vs AIS) and P<0.0001 using F test to compare variances. 
 
Ctrl
Pitx1 
-actin 
501 bp 
233 bp 
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3.2 Identification of a single nucleotide polymorphism in the Pitx1 promoter 
 
determine if 
this occurs due to inactivating mutations or other genetic alterations within the regulatory 
regions of the gene. Approximately 10 kb of the human Pitx1 promoter was analyzed in 
genomic DNA obtained from AIS (n=92) and control subjects (n=88) using Fluorescence 
Polarization–Single Base Extension (FP-SBE) technology, at McGill University and Genome 
Quebec Innovation Centre. We identified a G to A polymorphism (rs6867012) located at 
nucleotide position -3727, upstream of the transcriptional initiation site. Statistical analysis 
revealed that the heterozygous variant AG had a significant association with AIS (30.6%) than 
controls (18.4%), p=0.057 (Table 3.1). The occurrence of the homozygous variant AA was 
rare in AIS (3.4%) and controls (1.2%), with p=0.61. Interestingly, the SNP is located within 
an E2F-like binding site, which is of interest since E2Fs can stimulate Pitx1 expression [81]. 
E2F is a family of transcription factors. 
 
 
 
 
 
 
 
 
 
 
Once we confirmed the loss of Pitx1 expression in AIS patients, we wanted to 
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Table 3.1 A. Table shows the percentage of association of the homozygous wild type, 
able 3.1 B. Table shows the association of the Pitx1 polymorphism with clinical variables 
heterozygous and homozygous mutant Pitx1 polymorphisms with controls (n=92) and AIS 
(n=88) subjects. 
 
 
 
T
age and Cobb’s angle.  
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Figure 3.2: A cartoon depicting the E2F like site on the Pitx1 promoter. The base change
 
 
 
 
 
is at position -3727. 
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3.3 Presence of putative Hypoxia Response Element (HRE) on the promoter of human 
Pitx1 gene: 
 The hypoxia response element (HRE) consists of a core sequence 5’-RCGTG-3’ and is found 
within promoter and enhancer regions. 
Based on literature evidence that exposure to hypoxia in cells can down regulate a 
great number of genes, including Pitx1, we assumed it could be a direct target for the HIF 
transcription factors and may harbour functional hypoxia response elements within its 
promoter region. Using a web based Transcription Factors Binding Site Prediction tool [82], 
[83], we identified a potential 16bp HRE located between nucleotide  -1113 and -1097 with 
respect to the transcription initiation site (figure 3.3) 
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p300
 
 
Figure 3.3: Pitx1 hypoxia response element. A cartoon showing the position of the hypoxia 
response element within the Pitx1 promoter, which is bound by HIF- and  subunits along 
with their co-activator p300. 
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Table 3.2: List of a few known HREs that share sequence similarity (in uppercase) with the 
HRE found within the pitx1 promoter. 
 
 
Hypoxia response elements 
 
Gene 
 
Species 
 
gccctACGTGctgtctca 
 
Erythropoietin 
 
Human 
 
gagctACGTGcgcccgta 
 
GAPDH 
 
Human 
 
ggagtACGTGacggagcc 
 
Enolase 1 
 
Human 
 
gctgtACGTGcattggaa 
 
CAIX 
 
Human 
 
caactACGTGctctggtt 
 
IGFBP-1 
 
Human 
 
cagctACGTGcccacctc 
 
Cited2/p35srj 
 
Human 
 
cacatACGTGccacagtg 
 
ID2 
 
Human 
 
gccagACGTGcctggagt 
 
DEC1 
 
Human 
 
agctcACGTGcggaacgt 
 
DEC2 
 
Human 
 
tcgctACGTGcgctcagt 
 
Collagen prolyl 4-hydroxylase 
 
Rat 
 
ggtgtACGTGcagagcgc 
 
PHD2 
 
Human 
 
gggctACGTGcgctgcgt 
 
PHD3 
 
Human 
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3.4 Hypoxia Inducible Factors (HIF) bind to HRE in the Pitx1 promoter: 
To investigate whether Hypoxia inducible factors bound the HRE on the promoter 
region of Pitx1, we conducted an Electrophoretic Mobility Shift Assay (EMSA) using a radio-
labelled 24bp long double stranded probe 5’-CGACAAACTTCACCTACGTGCAAG-3’, 
(HRE-Pitx1 probe) and a cold probe containing the consensus HIF binding site 5’-
TCTGTACGTGACCACACTCAC-3’ (HIF CS probe) (Santa Cruz Biotechnology) as 
mentioned in Materials and Methods. 32P labeled DNA and protein complex were visualized 
after electrophoresis by autoradiography (Figure 3.4). In the absence of cold HIF CS probe, 
two complexes were detected, showing a strong association between the labeled HIF-Pitx1 
probe and proteins bound to it. The binding of both complexes were gradually reduced (Figure 
3.4, lane 3-5) using AIS nuclear extracts from competition experiments with molecular excess 
of consensus HRE binding sequences, while such an effect was less efficient with control 
nuclear extracts. Hence we conclude that the potential HRE present in the promoter of human 
Pitx1 is indeed bound by Hypoxia Inducible Factors. To further confirm this result, we 
competed the HRE-Pitx1 probe with an unrelated probe, which did not contain any HIF 
binding site (URP-Pitx1). As expected, there was no dissociation of the two radio-labeled 
HRE-Pitx1-protein complexes in the presence of molar excess of cold URP-Pitx1 probe. 
These findings confirm the fact that there is a functional HRE on the promoter of human Pitx1 
and that it is specific to Hypoxia Inducible factors.  
Moreover, we observed almost no DNA-protein complex dissociation with nuclear 
extract from control subjects compared to AIS nuclear extract, which is intriguing.  
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Figure 3.4: A. Determination of the putative HRE on Pitx1 promoter. Nuclear extracts 
from AIS osteoblasts (Lane 2-5) and control osteoblasts (Lane 6-9) were incubated with hot 
HRE-Pitx1 probe and molar excess of cold HIF CS probe for competition to analyze the 
specificity of the binding (Lane 3-5 and Lane 7-9). Lane 1 contains the free probe. Slower 
dissociation of the complex was observed with controls (Lanes 7-9) compared to AIS 
osteoblast nuclear extracts (Lane 3-5). 
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Figure 3.4 B: Determination of the specificity of HRE on Pitx1 promoter. Nuclear extract 
from AIS osteoblasts was incubated with hot HRE-Pitx1 probe (Lane a-d) and molar excess of 
cold unrelated probe URP-Pitx1 without any HIF binding site (Lane b-d) for competition. The 
HRE-protein complex did not dissociate with the competition, confirming the specificity of 
the Pitx1 HRE. 
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3.5 HIF-2 levels are significantly higher in AIS: 
 
To quantify and compare HIF-2 expression levels in AIS and controls, osteoblasts were 
cultured in 5cm petri dishes with  MEM under normoxia. First, cells were starved with serum 
free media for 24 hours, and harvested for RNA extraction after 6 hours, 16 hours, 24 hours 
within the starvation period. Next, the serum free media was removed and cells incubated with 
media containing 10% FBS for a period of 24 hours. Within this time period, cells were 
harvested at 6 hours, 16 hours, 20 hours and 24 hours for RNA extraction. 
After RNA extraction, cDNA was generated using RT-PCR for the quantification of HIF-2 
expression levels using qPCR. The levels of HIF-2 were significantly higher in AIS than 
controls at every corresponding interval of time (Figure 3.5). For example, HIF-2 levels were 
higher in AIS at 6 hours after starvation than in controls. Hence, our findings suggest that HIF-
2 is significantly up regulated in AIS osteoblasts even in normoxic conditions, which is quite 
atypical. 
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Figure 3.5: Real time PCR showing the expression pattern of HIF-2 in AIS and control 
osteoblasts after periods of serum starvation and supplementation. Normalization was done 
against the expression of -actin. 
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3.6 Regulation of Pitx1 promoter activity by hypoxia inducible factors in MG63 cells: 
 
To study the influence of hypoxia inducible factors on Pitx1, a proximal 4kb of Pitx1 promoter 
containing the HRE was cloned into a Luciferase reporter vector (pGL4-Pitx1). This plasmid 
was co-transfected into human osteoblastic cell lineMG-63 with expression vectors pCDNA- 
HIF-1 and HIF-2, and their  subunit pCDNA- ARNT and luciferase activity was determined. 
We used MG-63 cell line for this experiment since they are osteoblast-like cells and were 
easier to transfect than the primary cells. The luciferase activity of pGL4-Pitx1 was enhanced 
250 fold due to the co-expression of HIF-2 and ARNT, and 12.5 fold by HIF-1 (Figure 3.6). 
This was obtained after normalization using a co-transfected -galactosidase vector. This 
result suggests that HIF-2 has greater transcription activity than HIF-1 with respect to Pitx1-
HRE. 
1 
 
 
 
 
 
 
 
 
 
 
 
 60
A 
0
1
2
3
4
5
6
7
8
9
10
pGL4 Pitx1 pitx1+HIF1+ARNT
**
R
el
at
iv
e 
lu
ci
fe
ra
se
ac
tiv
ity
R
el
at
iv
e 
lu
ci
fe
ra
se
ac
tiv
ity
 
B 
0
50
100
150
200
250
300
pGL4 Pitx1 pitx1+HIF1+ARNT pitx1+HIF2+ARNT
**
**
R
el
at
iv
e 
lu
ci
fe
ra
se
ac
tiv
ity
R
el
at
iv
e 
lu
ci
fe
ra
se
ac
tiv
ity
 
 
Figure 3.6 Hypoxia inducible factors up regulate Pitx1 promoter activity. A. MG-63 cells 
were co-transfected with expression vectors pCDNA-HIF-1, pCDNA-ARNT and  luciferase 
reporter vector containing Pitx1 promoter with the HRE pGL4-pitx1. B. Co-transfection of 
MG-63 cells with pCDNA-HIF-2, pCDNA-ARNT and pGL4-Pitx1. Luciferase values were 
normalized using -galactosidase values. Statistical significance was determined using one 
way Anova test (P<0.0043) followed by Tukey’s multiple comparison test (P=**) 
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3.7 Regulation of Pitx1 promoter activity in osteoblasts derived from AIS and control 
subjects by hypoxia inducible factors: 
Osteoblasts from AIS and controls were co-transfected with the same set of plasmids and 
combinations mentioned in the previous section, to analyze the activity and regulation of Pitx1 
promoter. Interestingly, we found no significant Pitx1 promoter activity in AIS Osteoblasts, 
even after the addition of HIF2-alpha and ARNT. Whereas, Pitx1 promoter activity was 
enhanced by the over expression of HIF2- and ARNT (figure 3.7). The -galactosidase 
values from AIS osteoblasts were very similar to those obtained from control cells, confirming 
similar transfection efficiency in both the samples. 
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Figure 3.7: HIF-2 enhances Pitx1 promoter activity in controls, but not in AIS. AIS (A) 
and control osteoblasts (B) were transfected with expression vectors for HIF-1, HIF-2 and 
ARNT, along with pGL4-Pitx1 reporter vector. Luciferase values were normalized against co-
transfected -galactosidase values. Statistical significance was determined using one way 
Anova test. *** represents p<0.001. 
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Figure 3.7: C. Pitx1 promoter activity in AIS and control osteoblasts: Values obtained 
from two different experiments (n=2) including the ones above (figure 3.7 A and B) in AIS 
(violet histograms) and control (maroon histograms) were used to construct the graph. The *** 
represents P< 0.001, analyzed using one way Anova test.  
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3.8: Detection of SNP in the ODDD region of HIF-1 in AIS  
 
The existence of mutations or SNPs in the HIF-1 gene have been reported in different 
types of diseases, including prostrate cancer [84], colorectal cancer [85], cell carcinoma of the 
bladder [86] etc. The most significant polymorphism seems to be the rare C to T switch at 
position +1772, which corresponds to a Proline to a Serine change at position 582, within the 
oxygen dependant domain of HIF-1. This mutation increased the stability of the HIF-1 
protein even under normoxic conditions [84]. Due to its significance, we selected this 
polymorphism to be screened in AIS. 
Genomic DNA extracted from AIS (n=160)  and control (n=64) osteoblasts using 
standard protocol was sent to McGill University and Genome Quebec Innovation centre to 
determine the existence of P582S polymorphism in the HIF-1 gene. The technique used was 
Fluorescence Polarization – Single Base Extension (FP-SBE) technology.  
Data analysis revealed that occurrence of this rare polymorphism was higher in AIS 
samples compared to controls (Table 3.3). 
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Table 3.3: Table shows the percentage of association of homozygous wild type, heterozygous 
and mutant HIF-1 polymorphisms with AIS (n=160) and control subjects (n=64).  
 
 
   
AIS 
 
    
Control 
 
 
Genotype 
 
 
N 
  
% 
  
N 
  
% 
 
CC 
 
118/160 
  
73.75 
 
 
 
47/64 
  
73.43 
 
CT 
 
37/160 
  
23.1 
 
 
 
16/64 
  
25 
 
TT 
 
5/160 
  
3.1 
 
 
 
1/64 
  
1.56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 66
 
 
 
A.  
 
B. 
 
 
 
Figure 3.8: Sequence chromatograms obtained after sequencing AIS and control 
genomic DNA. The bases involved are circled in red, and dotted arrows indicate the peak 
representing them. Panel A represents the wild type (1772C) and panel B represents the 
mutant condition (1772T). 
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Chapter 4: Discussion: 
Research to understand the etiology of AIS is ongoing, because observations from 
previous studies weren’t conclusive enough, only proving that this disease is highly complex 
and involves multiple genes. Hence, our goal was to elucidate a specific molecular mechanism 
leading to the onset of scoliosis in adolescents. 
4.1 Pitx1 expression in AIS: 
As previously mentioned, the onset of scoliosis in Pitx1 transgenic mice prompted us 
to select Pitx1 as a candidate gene for the study. We observed a total loss of pitx1 expression 
in osteoblasts obtained from AIS subjects, compared to the controls. This was confirmed by 
real time PCR (Figure 3.1). Our finding is novel, and we conclude that there is a loss of Pitx1 
in AIS osteoblasts. The association of Pitx1 with AIS is further strengthened by the fact that 
even quadrupedal Pitx1+/- mice develop scoliosis, indicating the degree of severity and 
penetrance of the partial loss of Pitx1 expression to acquire such a phenotype. 
 
Our goal was to determine the cause of pitx1 repression in AIS. We explored mainly 
two possibilities. First, we screened approximately 10kb of pitx1 promoter region for 
mutations/single nucleotide polymorphisms affecting possibly its regulation, and found a 
known SNP (rs6867012) at position -3727 with respect to transcription initiation site. This 
SNP is of interest because it lies within an E2F-like site. E2Fs are known to activate pitx1 
[81]. However, we ruled out the possibility that this SNP has a major contribution towards 
inactivation of Pitx1 by abrogating E2F binding, because there are several other E2Fs sites 
that could activate Pitx1 expression, and it is highly unlikely that alteration of one single site 
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could completely prevent the activation of Pitx1 by E2Fs. So, we didn’t test the nature of the 
complex formed at the E2F-like site. However, we found a weak association of the SNP with 
AIS through statistical analysis. We propose that this SNP could be used as a genetic marker 
for AIS. 
4.2 Hypoxia inducible factors regulate Pitx1 promoter activity 
Second, we tested several possible factors that could induce the repression of Pitx1, 
based on literature knowledge. One of the candidates was hypoxia and hypoxia inducible 
factors HIF-1 and HIF-2 . Rivard et al [51] demonstrated a correlation between hypoxia and 
scoliosis in mice. Pregnant mice exposed to hypoxia on E 9.5 gave birth to pups with 
congenital scoliosis. Adolescent scoliosis is not congenital, but they share a lot of similar 
characteristics. [53]. 
We identified the presence of a potential HRE within the Pitx1 promoter 
approximately 1kb upstream of the site of initiation of transcription. Using consensus HRE 
probe as competition probe against the radio-labeled Pitx1-HRE probe in gel shift assay, we 
demonstrate for the first time that the Pitx1 gene contains the core HIF binding sequence 5’-
CGTGC- 3’, which makes Pitx1 a target gene of HIF factors. The gel shift assays also showed 
that competition with a cold consensus HRE probe resulted in dissociation of the DNA-protein 
complex in AIS sample, while no dissociation was observed in control sample. This could be 
possible due to the fact that HIF factors are expressed even under normoxia in AIS, resulting 
in their binding to Pitx1 HRE and dissociating in the presence of competitive probe.  
Although there is a high percentage of homology in the DNA binding domain of HIF-1 
and HIF-2 proteins, their other domains show very less similarity which may contribute to 
interaction with different co-factors and co-repressors, or selective binding of either factor to 
HREs within target promoters. Our future goal is to examine the mechanism behind the 
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preferential binding of HIF-2 alpha to the Pitx1-HRE in AIS by studying the nature of the 
transcription complex, using gel shift assay supplemented by mass spectrometry. Also, when 
we compared Pitx1 HRE to HREs found on other genes (table 3.2) we found that the former is 
strikingly similar to the HRE found on the human Erythropoietin gene. And recent work by 
researchers has shown that the Erythropoietin HRE is bound by HIF-2, and not HIF-1, as 
previously thought [87]. So we assume that HIF-2 might be the important one. Hence, it will 
be interesting to analyze the role of HIF-2 in AIS. 
4.2.1 Expression of HIF transcription factors: 
We tested the expression pattern of HIF-1 and HIF-2  using semi-quantitative PCR 
and quantitative PCR and observed elevated levels of both transcription factors in AIS even 
under normoxia, compared to controls. This finding is significant because over expression of 
HIFs are strongly associated with cancer pathogenesis [88] [77]. This has not been 
demonstrated before in the context of AIS, and we propose that over expression of HIFs could 
be an indicator of the severity and progression of idiopathic scoliosis. At the protein level, we 
expect to see a higher degree of stabilization of HIF-1 and HIF-2 proteins in AIS subjects. 
This will be eventually tested using Western blot and immuno- fluorescence methods.  
4.2.2 Identification of Proline to Serine mutation in the ODD of HIF-1: 
Since HIF-1 is the most well studied hypoxia transcription factor, we first thought that it was 
the key player in the regulation of Pitx1. SNP detection analysis using genomic DNA of AIS 
and control subjects identified a C to T change at base 1772 from the start codon resulting in 
the replacement of amino acid Proline at position 582 to a Serine in 3.1% of the AIS samples 
compared to 1.5% in controls tested (Figure 3.8). This rare mutation has been previously 
reported in prostrate cancer and colorectal cancer [84] [89]. The addition of Serine is known to 
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increase the stability and transcriptional activity of HIF-1 even under normoxia. The 
discovery of P582S mutation in some of the AIS subjects is intriguing. But one should keep in 
mind that AIS is highly heterogenous, so it not necessary to explain everything via HIF-1. 
Still, it will be interesting to test the functional consequence of this mutation in AIS and to 
determine whether or not those female patients are at risk of developing colorectal cancer 
during their adult life. 
 
4.2.3 Hypoxia inducible factors regulate Pitx1 promoter activity 
We demonstrated for the first time the presence of a putative HRE within the Pitx1 
promoter shown to be bound by HIF-2. Transfection assay experiments showed a 250 fold 
increase in pitx1 promoter activity in MG-63 cells when co-transfected with HIF-2 and 
ARNT expression vectors. HIF-1 and ARNT induced only a 12-fold increase, suggesting that 
Pitx1 HRE can be bound by either of the HIF factors in vitro and enhance pitx1 promoter 
function. The 250-fold increase of promoter activity induced by HIF-2 could mean that it is 
the dominant HIF with respect to Pitx1 hypoxia response element. Hence, our results suggest 
that HIF-2 is more potent than HIF-1 in activating Pitx1 transcription, which makes sense 
since the HRE found in human Pitx1 promoter is similar to other HRE activated by HIF-2 
[87] [90]. 
This result raises several questions. Pitx1 down regulation in cells treated with hypoxia 
have been previously reported. HIF-1 and HIF-2 are the two major players in the hypoxic 
response pathway. So we assumed that hypoxic down regulation of Pitx1 could be mediated 
through either of these factors. But transient transfection assays showed that Pitx1 promoter 
activity was being positively regulated by HIF-2 and ARNT in both MG63 and osteoblast 
cells from normal subjects (figures 3.6 A and 3.7 B). Interestingly, pitx1 promoter showed no 
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apparent activity in AIS osteoblasts, even with the addition of HIF-2 and ARNT. This leads 
us to two possible assumptions that: the presence of a repressor protein that competes with 
HIF-2 for the HRE binding site in AIS osteoblasts, thereby preventing HIF-2 mediated 
activation of Pitx1 promoter, or there maybe a co-repressor protein/complex in AIS 
Osteoblasts that can interact with HIF-2 and change its activity towards repression. 
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4.3 Hypothetical models  
4.3.1 Inhibition of Pitx1 via DEC1/DEC2; Two hypoxia inducible transcription factors. 
It has been previously demonstrated that hypoxia negatively regulated Pitx1 expression. So we 
postulated that this down-regulation maybe mediated through HIF-1 or HIF-2. On the 
contrary, they exhibited a positive influence on Pitx1 promoter activity, raising the possibility 
of involvement of other hypoxia induced transcription factors. 
 
Previous studies reported hypoxia mediated repression of genes like PPAR [91], human 
mismatch repair gene MLH1 [92] and STAT1 [93] by hypoxia induced transcription factors 
DEC1 (Differentially Expressed in Chondrocytes 1) and DEC2 (Differentially Expressed in 
Chondrocytes 2). They are members of the bHLH subfamily and play major roles in the 
regulation of adipogenesis, carcinogenesis and circadian rhythm. DEC1 is also known as split 
and hairy related protein (SHARP2) or stimulated with retinoic acid (STRA13), and DEC2 as 
bHLHB3 and SHARP1. They bind to E box or E box like motifs on the promoters of their 
targets, which mostly results in repression. An example for this is the repression of Human 
mismatch repair gene MLH1 by DEC1 and DEC2 via binding to a DEC response element. 
Other targets of these hypoxia induced transcriptional repressors include the sterol regulatory 
element binding protein-1c (SREBP-1c), fatty acid synthase (FAS) [94], and vascular 
endothelial growth factor (VEGF) [95]. Based on these studies, we assume that DEC1 or 
DEC2 might negatively regulate Pitx1 in AIS. 
 
 Interestingly, DEC1 and DEC2 contain hypoxia response elements and are regulated by HIF-
1 [96]. So we postulate that, in AIS, HIF-1 or HIF-2 could activate DEC1/DEC2 
transcription factors, which could bind to Pitx1 promoter and repress gene expression. 
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Moreover, DEC2 has been reported to be negatively regulating VEGF, a HIF-1 target. The 
inhibition occurs by the binding of DEC2 to HIF-1, which inhibits the binding of the latter to 
VEGF HRE, thereby, down regulating VEGF expression [95]. So we think that a similar 
mechanism might be responsible for the down regulation of Pitx1 in AIS osteoblasts. Hence, 
we will search for putative DEC1/DEC2 binding sites on Pitx1 promoter and study their effect 
on the latter’s activity through transient transfection assays. 
 
4.3.2 eIF3e/Int6 deregulation could lead to hyper activity of HIF-2 alpha in AIS 
eIF3e/Int6 is a tumor suppressor, which is also an e regulatory subunit of the 
eukaryotic translation initiation factor 3. It is a 48kDa protein with a PCI domain in the 
carboxyl terminal. Int6 was independently discovered during a study involving the insertion of 
mouse mammary tumor virus (MMTV) as a mutagen into the mouse Int6 gene. This insertion 
resulted in a dominant-negative C-terminal truncated Int6 protein, whose over-expression 
could transform cells. Injection of these Int6- transformed cells led to the development of 
tumors in nude mice.  
Chen et al., identified Int6/eIF3e to be regulating HIF-2  in a hypoxia and pVHL 
independent manner, using yeast two-hybrid analysis with HIF-2  C-terminal as bait. 
Moreover, Int6/eIF3e co-precipitated with HIF-2  and was found to co-localize together into 
the nucleus even under normoxia. Int6/eIF3e bound to HIF2, resulting in latter’s 
destabilization. Interestingly, yeast two hybrid analysis showed that Int6/eIF3e did not bind to 
HIF-1 or HIF-3 . Moreover, dominant negative mutant of Int6 resulted in an increase in the 
endogenous levels of HIF-2. Their results showed that interaction between Int6/eIF3e and 
HIF-2 results in the proteosomal degradation of the latter, even in cell lines that lacked 
endogenous pVHL expression [97]. 
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We think it could be possible that de-regulation Int6/eIF3e could result in the over expression 
and stabilization of HIF-2 in AIS, thereby playing a critical role in the onset of disease. Our 
initial step will be to test the expression levels of Int6/eIF3e at the mRNA and protein level in 
AIS and controls, HIF-2 protein expression in AIS and control osteoblasts co-transfected 
with Int6/eIF3e expression vector through western blot. 
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Chapter 5: Summary  
The main goal of this project was to study factors contributing to the etiopathogenesis 
of AIS. Using candidate gene driven approach, we chose Pitx1 as our gene of interest. We 
demonstrate for the first time a complete loss of Pitx1 in the osteoblasts of AIS patients, 
extracted from bone fragments obtained during spinal surgery. This result validates the first 
part of our hypothesis: that the expression of Pitx1 is affected in AIS. 
 
Researchers studying human diseases look for single nucleotide polymorphisms mostly 
exclusive to affected individuals and not to the general population. SNPs can be used as a 
biomarker and also in finding a susceptible genetic loci associated with a disease. We 
discovered a SNP within the Pitx1 promoter which had more association with AIS than 
controls, suggesting its role as a potential biomarker. We will conduct studies to see if this 
SNP have any functional consequence on Pitx1 transcription by facilitating binding of 
repressor protein complexes to the modified site using gel shift assays, and DNA pulldown 
followed by mass spectrometry. 
 
We demonstrated for the first time the existence of a functional hypoxia response element in 
the Pitx1 promoter. We expected to see a repression of pitx1 promoter activity by HIF-1 and 
HIF-2, but we were surprised to see them induce a 12 fold and 250 fold increases in luciferase 
activity respectively. We assume that there might be either other hypoxia inducible factors 
mediating the hypoxic down regulation of Pitx1 or co-repressors. However, there was no Pitx1 
promoter activity induction by HIF-2 in AIS osteoblasts. These observations raise several 
questions, which we will try to answer as part of an upcoming PhD project.  
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6. Relevance 
Our above finding is novel and is significant to ours and to other fields of study. Our work 
identifies Pitx1 as a major player in the etiology o AIS, therefore providing a more specific 
candidate for further studies. We hope that understanding the molecular mechanisms 
regulating Pitx1 will help us to explain the onset of scoliosis in adolescents.  
 
We also demonstrated that HIF factors bind to a hypoxia response element on Pitx1 promoter 
and regulate its expression. Our observation linking Pitx1 and HIF factors can be of interest 
also in the field of cancer research, because Pitx1 is a well studied tumor suppressor usually 
down regulated in various cancers (Table 1.2). It would be interesting to look at the 
relationship between Pitx1 and HIF-2 in different types of cancer cell lines, and how it can 
influence tumor formation and severity. 
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